The changes in MLD from six to 24 months in the target lesions were significantly lower in the rosuvastatin group than in the non-statin group among the patients treated with drug-eluting stents ( -0.046 0.108 mm vs. -0.133 0.108 mm , p = 0.009 ) versus those treated with bare-metal stents ( -0.011 0.094 mm vs. -0.015 0.040 mm , p = 0.255 ) .